Lawrence Wickerham
Invasive Breast Cancer Chemoprevention Trials Assessed
REFERENCE: ABSTRACT Special Session; American Association for Cancer Research Centennial Meeting, April 14-18, Los Angeles
LAWRENCE WICKERHAM, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh
The best options for preventing invasive breast cancer among women at high risk were assessed at the AACR meeting. Lawrence Wickerham talked about the latest results from chemoprevention trials, which point to a need to rethink the way tamoxifen, raloxifene, and the aromatase inhibitors should be used. In Los Angeles he discussed his conclusions and recommendations with Karen Regester.
LAWRENCE WICKERHAM, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh
The best options for preventing invasive breast cancer among women at high risk were assessed at the AACR meeting. Lawrence Wickerham talked about the latest results from chemoprevention trials, which point to a need to rethink the way tamoxifen, raloxifene, and the aromatase inhibitors should be used. In Los Angeles he discussed his conclusions and recommendations with Karen Regester.
Stanley Gall
Five and a Half Year Results: Bivalent Human Papillomavirus Vaccine Success
REFERENCE: ABSTRACT 4900, American Association for Cancer Research Centennial Meeting, April 14-18, Los Angeles
STANLEY GALL, University of Louisville, Kentucky
Latest data on the bivalent human papillomavirus vaccine for cervical cancer, showing continuing protection, were presented at the American Association for Cancer Research Annual Meeting in Los Angeles. With five and a half years of follow up, Stanley Gall discussed with Karen Regester the success of the vaccine.
STANLEY GALL, University of Louisville, Kentucky
Latest data on the bivalent human papillomavirus vaccine for cervical cancer, showing continuing protection, were presented at the American Association for Cancer Research Annual Meeting in Los Angeles. With five and a half years of follow up, Stanley Gall discussed with Karen Regester the success of the vaccine.
Andrew Lepisto
Theresa Whiteside
Autologous Vaccine: Benefit for Patients With Resectable Pancreatic Cancer?
REFERENCE: ABSTRACT 4896; American Association for Cancer Research Centennial Meeting, April 14-18, Los Angeles
ANDREW LEPISTO, University of Pittsburgh
THERESA WHITESIDE, University of Pittsburgh
An autologous vaccine for pancreatic cancer offers the hope of improving survival, and perhaps even cure, among patients who have resectable tumors. Peter Goodwin talked about the latest findings with Andrew Lepisto, and he asked Theresa Whiteside to give her assessment of the new data.
ANDREW LEPISTO, University of Pittsburgh
THERESA WHITESIDE, University of Pittsburgh
An autologous vaccine for pancreatic cancer offers the hope of improving survival, and perhaps even cure, among patients who have resectable tumors. Peter Goodwin talked about the latest findings with Andrew Lepisto, and he asked Theresa Whiteside to give her assessment of the new data.
To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.
